Tryptamine Therapeutics Completes Dosing in Phase 1 Psilocin Trial on Obese Individuals; Shares Rise 5%

MT Newswires Live

Nov 29, 2024

Tryptamine Therapeutics (ASX:TYP) completed the dosing component of its phase 1b trial, administering the intravenous-infused psilocin TRP-8803 in three obese individuals, according to a Friday filing with the Australian bourse.

Psilocin is used in psychedelic-assisted psychotherapy and has potential neuroplastic benefits, which may help in providing structural and functional changes in the brain.

The trial aims to compare the pharmacokinetic profile of psilocybin in obese individuals with non-obese individuals, the filing said.

Results will be used to advance the program into a phase 2 trial investigating the use of TRP-8803 in weight-related indications such as binge-eating disorder, the filing added.

Company shares rose nearly 5% in recent Friday trade.

Price (AUD): $0.05, Change: $+0.002, Percent Change: +4.65%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2487230111"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2487230111\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2487230111?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-29 12:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2487230111","market":"sh","top_or_hot":-1,"title":"Tryptamine Therapeutics Completes Dosing in Phase 1 Psilocin Trial on Obese Individuals; Shares Rise 5%","media":"MT Newswires Live","content":"<html><body><p> Tryptamine <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:TYP) completed the dosing component of its phase 1b trial, administering the intravenous-infused psilocin TRP-8803 in three obese individuals, according to a Friday filing with the Australian bourse.</p><p>Psilocin is used in psychedelic-assisted psychotherapy and has potential neuroplastic benefits, which may help in providing structural and functional changes in the brain.</p><p>The trial aims to compare the pharmacokinetic profile of psilocybin in obese individuals with non-obese individuals, the filing said.</p><p>Results will be used to advance the program into a phase 2 trial investigating the use of TRP-8803 in weight-related indications such as binge-eating disorder, the filing added.</p><p>Company shares rose nearly 5% in recent Friday trade.</p><p>Price (AUD): $0.05, Change: $+0.002, Percent Change: +4.65%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tryptamine Therapeutics Completes Dosing in Phase 1 Psilocin Trial on Obese Individuals; Shares Rise 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTryptamine Therapeutics Completes Dosing in Phase 1 Psilocin Trial on Obese Individuals; Shares Rise 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-29 12:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tryptamine <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:TYP) completed the dosing component of its phase 1b trial, administering the intravenous-infused psilocin TRP-8803 in three obese individuals, according to a Friday filing with the Australian bourse.</p><p>Psilocin is used in psychedelic-assisted psychotherapy and has potential neuroplastic benefits, which may help in providing structural and functional changes in the brain.</p><p>The trial aims to compare the pharmacokinetic profile of psilocybin in obese individuals with non-obese individuals, the filing said.</p><p>Results will be used to advance the program into a phase 2 trial investigating the use of TRP-8803 in weight-related indications such as binge-eating disorder, the filing added.</p><p>Company shares rose nearly 5% in recent Friday trade.</p><p>Price (AUD): $0.05, Change: $+0.002, Percent Change: +4.65%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2487230111","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2487230111","pubTimestamp":1732856080,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tryptamine Therapeutics  completed the dosing component of its phase 1b trial, administering the intravenous-infused psilocin TRP-8803 in three obese individuals, according to a Friday filing with the Australian bourse.Psilocin is used in psychedelic-assisted psychotherapy and has potential neuroplastic benefits, which may help in providing structural and functional changes in the brain.The trial aims to compare the pharmacokinetic profile of psilocybin in obese individuals with non-obese individuals, the filing said.Results will be used to advance the program into a phase 2 trial investigating the use of TRP-8803 in weight-related indications such as binge-eating disorder, the filing added.Company shares rose nearly 5% in recent Friday trade.Price : $0.05, Change: $+0.002, Percent Change: +4.65%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK7096":"制药","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","BK4139":"生物科技","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","BK4125":"广播","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC"},"translate_title":"Tryptamine Therapeutics在肥胖个体的1期裸盖菇素试验中完成给药；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"TYP.AU":0.9,"LENZ":1},"content_text":"Tryptamine Therapeutics (ASX:TYP) completed the dosing component of its phase 1b trial, administering the intravenous-infused psilocin TRP-8803 in three obese individuals, according to a Friday filing with the Australian bourse.Psilocin is used in psychedelic-assisted psychotherapy and has potential neuroplastic benefits, which may help in providing structural and functional changes in the brain.The trial aims to compare the pharmacokinetic profile of psilocybin in obese individuals with non-obese individuals, the filing said.Results will be used to advance the program into a phase 2 trial investigating the use of TRP-8803 in weight-related indications such as binge-eating disorder, the filing added.Company shares rose nearly 5% in recent Friday trade.Price (AUD): $0.05, Change: $+0.002, Percent Change: +4.65%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}